Deep Apple could receive up to $812 million in payments plus royalties from Novo Nordisk. Novo Nordisk gains exclusive global rights to commercialize oral GPCR-targeted drugs. Get daily-updated ...

Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk. In total, Deep Apple will be eligible to receive up to $812 million in payments, as ...

Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk. In total, Deep Apple will be eligible to receive up to $812 million in payments, as well ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:NVO) to discover, develop, and commercialize ...

Founded by Apple Tree Partners (ATP), Deep Apple combines ensemble cryo-EM to explore receptor conformations, deep learning, and the docking of multi-billion virtual compound libraries generated using ...

Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:NVO) to discover, develop, and commercialize ...